Jean Vandromme

No ORCID on file · 4 papers in corpus · active 2015-2021

Study types

  • review 2
  • article 1
  • editorial 1

Condition tags

  • endometriosis 3
review 2021
Menopausal hormone therapy and breast cancer risk
Best practice & research. Clinical endocrinology & metabolism ·doi:10.1016/j.beem.2021.101577

This narrative review analyses the customization of Menopause Hormone Therapy in the context of breast cancer risk in women with premature ovarian insufficiency (POI) and with menopause at a normal age. Women with Idiopathic POI, FMR-1 prem…

article 2019
Attitudes to the prescription of menopause hormone therapy for vasomotor symptoms and osteoporosis for patients of different ages: A survey of gynecologists in Belgium
·doi:10.1016/j.maturitas.2019.07.024
review 2017
The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology
The Australian & New Zealand journal of obstetrics & gynaecology ·doi:10.1111/ajo.12641

This review discusses the development of selective progestin receptor modulators (SPRMs) for use in women's health and specifically the use of ulipristal acetate (UPA) as emergency contraception (EC) and as a treatment for symptomatic fibro…

editorial 2015
Should we abstain from treating women with endometriosis using menopausal hormone therapy, for fear of an increased ovarian cancer risk?
Climacteric : the journal of the International Menopause Society ·doi:10.3109/13697137.2015.1041905

Women suffering from endometriosis often have an early menopause, resulting in severe menopausal symptoms and an increased risk of osteoporosis. They are therefore candidates for menopausal hormone therapy (MHT). Unfortunately, MHT may incr…